Fosbretabulin disodium(CA 4DP; CA 4P) is a microtubule destabilizing drug, a type of vascular-targeting agent, a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.

Fosdagrocorat (PF 04171327) is an orally available, potential dissociated agonist of the glucocorticoid receptor (GR) for the treatment of rheumatoid arthritis, the phosphate ester prodrug of PF-00251802 (dagrocorat)..

Fosfluconazole (INN) is a water-soluble phosphate prodrug of fluconazole

Foslinanib (TRX-818) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities, induces cancer cell apoptosis and inhibits cancer cell proliferation.

Fosmidomycin sodium salt is a phosphonic acid antibiotic and a antimalarial drug, which is active against both Gram-negative and Gram-positive bacteria.

Fosravuconazole is a prodrug of ravuconazole, with antifungal activity.

Fostamatinib (R788) is a prodrug of the active metabolite R406, which is a potent, ATP-competitive inhibitor of Syk kinase with Ki/IC50 of 30/41 nM.

Fosteabine is an oral and prodrug analogue of cytarabine which is resistant to deoxycytidine deaminase.

Foxy-5 is a novel Wnt-5A mimicking hexapeptide that inhibits breast cancer metastasis in vivo by targeting cell motility.

FPL64176 is a potent L-type Ca++ channel activator with EC50 of 16 nM.

FQI1 is a small-molecule inhibitor of transcription factor LSF with IC50 of 2.1 uM.

FQI2 is a small-molecule inhibitor of transcription factor LSF with IC50 of 0.71 uM.

FR 900098 is a derivative of fosmidomycin that inhibits DOXP reductoisomerase, demonstrates antimalarial activity with IC50 of 170, 170, and 90 nM for HB3, A2, and Dd2 P. falciparum strains, respectively..

FR194738 is a squalene epoxidase inhibitor. FR194738 inhibits squalene epoxidase activity in HepG2 cell homogenates with an IC50 of 9.8 nM.

FR58P1a is a mitochondrial metabolism-affecting compound that uncouples OXPHOS through a protonophoric mechanism, selectively inhibits migration in triple-negative breast cancer cells via Sirt1/AMPK/β1-integrin pathway.

FR-901464 is a potent antitumor natural product that binds to the splicing factor 3b (SF3b) complex and inhibits pre-mRNA splicing, inhibits cell cycle progression at G1 and G2/M phases..

Framycetin (Fradiomycin B; Neomycin B) is an aminoglycoside antibiotic. It inhibits hammerhead ribozyme with a Ki of 13.5 μM.

Framycetin sulphate

FRAX1036 is a novel ATP-competitive small molecule inhibitor of group I p21-activated Kinases (PAKs).

FRAX486 is a selective inhibitor of group I PAKs with IC50s of 8.25/39.5, /55.3 nM for PAK1/PAK2/PAK3 respectivelt; less potent for PAK4(IC50=779 nM).

Frentizole, an FDA-approved immunosuppressive drug, is a novel inhibitor of the Aβ-ABAD interaction.

Frovatriptan Succinate is the succinate salt form of frovatriptan, a synthetic triptan with serotonin (5-HT) receptor agonist activity especially for the 5-HT1B/1D receptors.